Discovery of Inhibitory Fragments That Selectively Target Spire2–FMN2 Interaction
Radoslaw Kitel, Ewa Surmiak, Jan Borggräfe, Justyna Kalinowska-Tluscik, Przemyslaw Golik, Miroslawa Czub, Wiktor Uzar, Bogdan Musielak, Mariusz Madej, Grzegorz M. Popowicz, Grzegorz Dubin, Tad A. Holak · 2023
Read Discovery of Inhibitory Fragments That Selectively Target Spire2–FMN2 Interaction by Radoslaw Kitel, Ewa Surmiak, Jan Borggräfe, Justyna Kalinowska-Tluscik, Przemyslaw Golik, Miroslawa Czub, Wiktor Uzar, Bogdan Musielak, Mariusz Madej, Grzegorz M. Popowicz, Grzegorz Dubin, Tad A. Holak (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10726347.txt.
Description
Radoslaw Kitel and co-authors report a 2023 hunt for small drug fragments that block one protein pairing but not a close twin. The pairings involve Spire2 or Spire1, each binding the protein FMN2. Blocking only the Spire2 pairing could give a clean research probe. The team screened a house library of 755 compounds with a heat-based test.
Hits were checked with several other lab methods, including light-based and magnetic tests. The team then varied the chemistry step by step to boost strength. One compound reached micromolar strength with high ligand efficiency. Docking models helped explain how it binds. The fragment is a checked starting point for building selective probes.
Catalog record
| CREATOR | Radoslaw Kitel, Ewa Surmiak, Jan Borggräfe, Justyna Kalinowska-Tluscik, Przemyslaw Golik, Miroslawa Czub, Wiktor Uzar, Bogdan Musielak, Mariusz Madej, Grzegorz M. Popowicz, Grzegorz Dubin, Tad A. Holak |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |